PharmExec Blog

Without An Rx, Some Pharmas Are Skittish

Nestle's Boost Glucose ControlLower margins and strong-arm direct-to-consumer campaigns are two of the primary barriers to selling nutraceuticals, according to a business school ‘war game’ conducted with the participation of Abbott, Danone (Dannon in the US), GSK and Nestlé. But the global nutraceuticals market – worth $80 billion in 2010, according to Frost & Sullivan – is expected to grow substantially in the next few years, unlike prescription drug spending.

The companies listed above – Abbott and GSK, on the one hand, and Danone and Nestlé, on the other – represent two distinctly different industries that are beginning to step on each other’s toes.  Consumer packaging goods (CPG) companies are skilled at developing and marketing consumer products, while pharma’s expertise is more science-oriented, in terms of product development and marketing requirements. Both industries have taken notice of a snowballing consumer interest in so-called nutraceuticals and functional foods, or products that don’t necessarily involve active pharmaceutical agents, but have marketable, science-based ingredients.

While Abbott, GSK, Sanofi and other pharmas have shown an interest in building a nutraceuticals or science-tempered nutritionals business around areas like heart disease, Alzheimer’s, diabetes and gastrointestinal disorders, others have shied away from the prospect of low margin consumer products, and the marketing efforts they require. Pfizer, for example, put Wyeth’s baby formula business up for sale in July; Nestlé and Danone are reportedly the leading bidders.

Given the pipeline gap, pharma can’t afford to cede the nutraceuticals market to CPGs like Nestlé, a company that is actively climbing over the fence into pharmaceuticals. Pharma companies are “gun shy” about aggressive consumer marketing, and less willing to take risks, says Leonard Fuld, CEO of Fuld & Company, a competitive intelligence firm, and host to the aforementioned war games. Pharma’s FDA regulatory funambulism is the source of its reticence, whereas CPGs are willing to risk obtrusiveness (and legal grey areas) in the attempt to dominate a market. You won’t see embedded video advertising for a pharma brand placed against pirated television shows hosted offshore, for example.

Fuld says the war game discussions also revealed that pharma companies are nervous about partnerships with CPGs, believing that brand identity or intellectual property could be usurped after handing over a product. While Nestlé in particular could “break the mold” – the company has walled off its high-science division, separating disciplines like genomics, biochemistry and human cell biology, from say, innovations in foam-boosted cappuccinos – Fuld says pharma companies need to make a public health case for nutraceuticals, since they don’t know how to educate consumers the CPG way: by creating and exploiting a broad, populist market need. CPGs like Nestlé and Danone are pushing into new, science-based products that don’t require a prescription. Fuld says pharma should be more willing to collaborate, and recognize the nutraceuticals and “designer foods” market for what it is: an opportunity for new revenue that bypasses a decade-long testing phase and an increasingly hostile payer environment.

Participants representing the four companies in the war game were culled from Dartmouth’s Tuck School, MIT Sloan, Northwestern’s Kellogg School, and the Yale School of Management. Actual company representatives observed and made comments.

This entry was posted in Advertising, Global, IP, Marketing, patient education, Regulatory, Strategy and tagged , , , . Bookmark the permalink. Trackbacks are closed, but you can post a comment.

4 Comments

  1. Michael Swit
    Posted August 25, 2011 at 2:15 pm | Permalink

    Using the term “nutraceutical” here confuses the thrust of your story. Many people, including Health Canada, regard nutraceuticals as those dietary supplements sold with a health claim. If a traditional food (e.g., oatmeal) bears a health claim, that typically is called a functional food by most. Your article fail to distinguish these two terms with precision, in my view.

  2. Posted August 25, 2011 at 4:54 pm | Permalink

    Thanks Michael, but I wonder if there is always a clear distinction between the two terms. For example, would you consider health drinks like GSK’s Boost (pictured above, with the claim “Great for people with diabetes”), which contains dietary supplements like folate, iron, calcium and several other vitamins to be a nutraceutical, a functional food, or neither? To what extend does a product’s packaging and promotion, as opposed to its ingredients, determine how it will be classified?

  3. ted whitby
    Posted August 31, 2011 at 9:34 am | Permalink

    In my view, if it is a food or drink foremost, it is a functional food. If it is a supplement first and foremost, then it is a nutraceutical. Boost and Glucerna are functional foods, while 5-Hour Energy is a nutraceutical. Granted this can be a fine line and influenced by how a brand is marketed. Nonetheless, when I read the headline I assumed the topic was supplements.

  4. Adrianne
    Posted September 16, 2011 at 12:09 am | Permalink

    Functional food is defined by the FDA as a regulatory classification.

Post a Comment

Your email is never published nor shared. Required fields are marked *

*
*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

  • Categories

  • Meta